Lundbeck’s Serdolect and AstraZeneca’s Seroquel XR To Face Advisory Panel Review
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s Psychopharmacologic Drug Advisory Committee will evaluate the applications for the two antipsychotics in a two day meeting in April.
You may also be interested in...
Metoclopramide Gets Boxed Warning, REMS, For Movement Disorder Risk
FDA issued a class-wide requirement Feb. 26 for metoclopramide-containing products to gain a boxed warning and Risk Evaluation and Mitigation Strategy to address the gastrointestinal drug's associated risk of tardive dyskinesia
AstraZeneca Internal Seroquel Documents Cite Cherry-Picking, Burying Data
AstraZeneca agreed to unseal internal communications in Seroquel product liability litigation discussing risks associated with the drug.
AstraZeneca Submits Seroquel XR In Two Additional Indications
Company is seeking approval of separate sNDAs for treatment of bipolar mania and bipolar depression.